Buscar
Shattuck Labs Inc
STTKAñadir a la lista de seguimiento
6.260USD
-0.410-6.15%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
473.14MCap. mercado
PérdidaP/E TTM
Más Datos de Shattuck Labs Inc Compañía
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Información de Shattuck Labs Inc
Símbolo de cotizaciónSTTK
Nombre de la empresaShattuck Labs Inc
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoSchreiber (Taylor)
Número de empleados44
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 09
Dirección500 W. 5Th Street
CiudadAUSTIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal78701
Teléfono15129004690
Sitio Webhttps://www.shattucklabs.com/
Símbolo de cotizaciónSTTK
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoSchreiber (Taylor)
Ejecutivos de Shattuck Labs Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
--
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
80.56K
-1.20%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
--
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
80.56K
-1.20%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
9.62%
OrbiMed Advisors, LLC
8.22%
Adage Capital Management, L.P.
8.22%
Redmile Group, LLC
7.22%
NEXTBio Capital Management LP
4.11%
Otro
62.60%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
9.62%
OrbiMed Advisors, LLC
8.22%
Adage Capital Management, L.P.
8.22%
Redmile Group, LLC
7.22%
NEXTBio Capital Management LP
4.11%
Otro
62.60%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
18.05%
Investment Advisor/Hedge Fund
17.65%
Hedge Fund
16.84%
Private Equity
8.22%
Corporation
4.08%
Family Office
2.13%
Research Firm
1.79%
Individual Investor
1.18%
Pension Fund
0.03%
Otro
30.02%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
189
50.41M
65.78%
+9.74M
2025Q4
187
35.93M
56.78%
+4.02M
2025Q3
179
32.72M
51.71%
-1.24M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
7.37M
10.3%
+6.02M
+444.29%
Jan 31, 2026
OrbiMed Advisors, LLC
6.31M
8.81%
--
--
Dec 31, 2025
Adage Capital Management, L.P.
6.31M
8.81%
--
--
Dec 31, 2025
Redmile Group, LLC
5.54M
7.74%
--
--
Dec 31, 2025
NEXTBio Capital Management LP
3.15M
4.4%
+3.15M
--
Dec 31, 2025
Houghton Capital Holdings, LLC
2.61M
3.65%
--
--
Apr 01, 2025
Prosight Capital
2.38M
3.33%
-3.07M
-56.31%
Dec 31, 2025
T. Rowe Price Associates, Inc.
1.93M
2.69%
+1.89M
+5515.57%
Dec 31, 2025
The Clark Estates Inc.
1.48M
2.06%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
Ver más
Texas Capital Texas Equity Index ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Morningstar Small-Cap ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Texas Capital Texas Small Cap Equity Index ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
